LUCA Biologics

Undisclosed RD/Clin0 preterm birth; undisclosed RD bacterial vaginosis

LUCA Biologics is developing living medicines that target the vaginal microbiome for urogenital and reproductive health. The vaginal microbiome has a symbiotic relationship with the human host and plays critical roles in maintaining health. Imbalance can impact menstruation, fertility and pregnancy as well as contributing to urinary tract infection and bacterial vaginosis. LUCA is devising ways to modulate the vaginal microbiome using microbiota-based therapeutics to protect, restore and sustain homeostatic function of the ecosystem. LUCA’s first therapy is due to enter the clinic soon targeting urinary tract infections.

Jobs: